Veeva Acquires Ostro to Expand AI-Driven Brand Engagement
Veeva Systems has announced the acquisition of Ostro bringing the AI-driven brand engagement platform into its expanding commercial ecosystem.
Ostro provides conversational AI experiences that allow patients and healthcare professionals to ask questions on pharmaceutical brand websites and receive MLR-approved information, resources, and guidance in real time. The platform combines conversational AI, semantic search, and industry-specific compliance guardrails to ensure responses are drawn from approved materials rather than generating new or unverified content.
The platform also captures engagement data that can help pharmaceutical brands better understand user behaviour and refine digital engagement strategies.
Ostro will continue operating as an independent unit led by CEO Chase Feiger, with plans to integrate its capabilities with the Veeva Commercial Cloud over time. According to Veeva, this could enable more connected workflows linking digital engagement with field and commercial activities.
solli’s Final Thoughts
The acquisition highlights the growing role of AI-driven conversational engagement in the pharma marketing ecosystem, something we’ve long discussed on solli. As audiences increasingly expect immediate answers online, pharmaceutical brands are exploring new ways to deliver compliant information through interactive formats.
This focus on Ostro by Veeva suggest that conversational interfaces will continue to increased in importance as a complement to traditional brand websites, search strategies, and HCP media channels, particularly as companies look to connect digital engagement data with broader commercial and media strategies.
